[go: up one dir, main page]

MX2019003099A - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX2019003099A
MX2019003099A MX2019003099A MX2019003099A MX2019003099A MX 2019003099 A MX2019003099 A MX 2019003099A MX 2019003099 A MX2019003099 A MX 2019003099A MX 2019003099 A MX2019003099 A MX 2019003099A MX 2019003099 A MX2019003099 A MX 2019003099A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
salmeterol
component
hfa
difluoroethane
Prior art date
Application number
MX2019003099A
Other languages
English (en)
Other versions
MX384545B (es
Inventor
James Noakes Timothy
Corr Stuart
Original Assignee
Mexichem Fluor Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1615914.7A external-priority patent/GB2554091A/en
Priority claimed from GBGB1620517.1A external-priority patent/GB201620517D0/en
Application filed by Mexichem Fluor Sa De Cv filed Critical Mexichem Fluor Sa De Cv
Publication of MX2019003099A publication Critical patent/MX2019003099A/es
Publication of MX384545B publication Critical patent/MX384545B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición farmacéutica. La composición comprende: (i) un componente de fármaco que comprende al menos un compuesto de salmeterol seleccionado de salmeterol y derivados aceptables desde el punto de vista farmacéutico de este; y (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a).
MX2019003099A 2016-09-19 2017-09-18 Composicion farmaceutica MX384545B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1615914.7A GB2554091A (en) 2016-09-19 2016-09-19 Pharmaceutical composition
GBGB1620517.1A GB201620517D0 (en) 2016-12-02 2016-12-02 Pharmaceutical composition
PCT/GB2017/052764 WO2018051133A1 (en) 2016-09-19 2017-09-18 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2019003099A true MX2019003099A (es) 2019-06-10
MX384545B MX384545B (es) 2025-03-14

Family

ID=59997388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003099A MX384545B (es) 2016-09-19 2017-09-18 Composicion farmaceutica

Country Status (10)

Country Link
US (4) US10792256B2 (es)
EP (1) EP3515425B1 (es)
JP (1) JP6781828B2 (es)
CN (1) CN109715148A (es)
AU (1) AU2017328910B2 (es)
CA (1) CA3037107C (es)
ES (1) ES2877575T3 (es)
MX (1) MX384545B (es)
WO (1) WO2018051133A1 (es)
ZA (1) ZA201902051B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
EP3607936B1 (en) * 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate
KR102279445B1 (ko) * 2016-09-19 2021-07-22 멕시켐 플루어 소시에다드 아노니마 데 카피탈 바리아블레 약제학적 조성물
CA3037107C (en) * 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
EP3880169B1 (en) * 2018-11-12 2025-07-23 Kindeva Drug Delivery L.P. Umeclidinium and vilanterol formulation and inhaler
CN112438966B (zh) * 2019-08-30 2022-08-26 四川普锐特药业有限公司 一种医用定量吸入气雾剂
JP2023513969A (ja) * 2020-02-20 2023-04-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 緩衝化医薬製剤を含む加圧定量吸入器
GB2597758A (en) * 2020-08-03 2022-02-09 Mexichem Fluor Sa De Cv Pharmaceutical composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9024366D0 (en) 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
EE9700138A (et) * 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
AU750567B2 (en) 1997-09-29 2002-07-25 Novartis Ag Stabilized preparations for use in nebulizers
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6103266A (en) 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
CN1144582C (zh) 2000-11-28 2004-04-07 中国药科大学 治疗呼吸系统疾病的无氟里昂药用气雾剂
CN1216600C (zh) 2002-04-24 2005-08-31 信谊药厂 盐酸左旋沙丁胺醇气雾剂及制备工艺
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
EP2322243A1 (en) 2002-08-29 2011-05-18 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
CN1726038A (zh) 2002-12-16 2006-01-25 贝林格尔英格海姆法玛两合公司 含有噻托铵的hfc溶液剂
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060018840A1 (en) 2004-06-28 2006-01-26 Nektar Therapeutics Aerosolizable formulation comprising nicotine
ES2259915B1 (es) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion.
WO2007020204A2 (en) 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
CN104918604A (zh) 2012-10-23 2015-09-16 西普拉有限公司 药物组合物
EP3383366B2 (en) * 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CA3037107C (en) * 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising salmeterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
EP3607936B1 (en) * 2016-09-19 2023-11-08 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising glycopyrrolate

Also Published As

Publication number Publication date
CA3037107C (en) 2021-05-18
BR112019005168A2 (pt) 2019-06-11
JP6781828B2 (ja) 2020-11-04
CA3037107A1 (en) 2018-03-22
ZA201902051B (en) 2024-10-30
US10792256B2 (en) 2020-10-06
AU2017328910B2 (en) 2020-04-09
ES2877575T3 (es) 2021-11-17
US11077076B2 (en) 2021-08-03
US20200281874A1 (en) 2020-09-10
US20190274973A1 (en) 2019-09-12
US11883372B2 (en) 2024-01-30
WO2018051133A1 (en) 2018-03-22
US11311502B2 (en) 2022-04-26
CN109715148A (zh) 2019-05-03
JP2019529427A (ja) 2019-10-17
AU2017328910A1 (en) 2019-04-04
EP3515425B1 (en) 2021-06-09
US20200281875A1 (en) 2020-09-10
US20220202746A1 (en) 2022-06-30
MX384545B (es) 2025-03-14
EP3515425A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
MX2019003099A (es) Composicion farmaceutica.
CO2019002556A2 (es) Composición farmacéutica
MX2019003105A (es) Composicion farmaceutica.
MX386777B (es) Composición farmacéutica que comprende un compuesto de tiotropio.
CO2019002555A2 (es) Composición farmacéutica
MX2018006800A (es) Composicion farmaceutica.
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
ZA202006535B (en) Pharmaceutical composition comprising salbutamol
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
MX2019008302A (es) Inhibidores biciclicos de histona desacetilasa.
MX2018006799A (es) Composicion farmaceutica.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
MX2017015812A (es) Formulaciones farmaceuticas inyectables de lefamulina.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CL2022001314A1 (es) Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
EA201990506A1 (ru) Фармацевтическая композиция
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
CO2021018010A2 (es) Composiciones de diclorfenamida y métodos de uso
CL2018000359A1 (es) Fenoxiacetamidas apareadas novedosas
CL2018000310A1 (es) Benzamidas apareadas novedosas
UA130656U (uk) Композиція з протитуберкульозною дією
AR102978A1 (es) Formulación de relación fija de insulina glargina / lixisenatida